Read by QxMD icon Read

Inform study relapsed cancer

Flora Stavridi, Konstantine T Kalogeras, Kyriaki Pliarchopoulou, Ralph M Wirtz, Zoi Alexopoulou, Flora Zagouri, Elke Veltrup, Eleni Timotheadou, Helen Gogas, Angelos Koutras, Georgios Lazaridis, Christos Christodoulou, George Pentheroudakis, Apostolos Laskarakis, Petroula Arapantoni-Dadioti, Anna Batistatou, Maria Sotiropoulou, Gerasimos Aravantinos, Pavlos Papakostas, Paris Kosmidis, Dimitrios Pectasides, George Fountzilas
BACKGROUND-AIM: Early breast cancer is a heterogeneous disease, and, therefore, prognostic tools have been developed to evaluate the risk for distant recurrence. In the present study, we sought to develop a risk for recurrence score (RRS) based on mRNA expression of three proliferation markers in high-risk early breast cancer patients and evaluate its ability to predict risk for relapse and death. In addition the Adjuvant! Online score (AOS) was also determined for each patient, providing a 10-year estimate of relapse and mortality risk...
2016: PloS One
Tsukasa Ikeura, Hideaki Miyoshi, Masaaki Shimatani, Kazushige Uchida, Makoto Takaoka, Kazuichi Okazaki
Autoimmune pancreatitis (AIP) has been considered a favorable-prognosis disease; however, currently, there is limited information on natural course of AIP during long-term follow-up. Recently published studies regarding the long-term outcomes of AIP has demonstrated the developments of pancreatic stone formation, exocrine insufficiency, and endocrine insufficiency are observed in 5%-41%, 34%-82%, and 38%-57% of patients having the disease. Furthermore, the incidence rate of developing pancreatic cancer ranges from 0% to 4...
September 14, 2016: World Journal of Gastroenterology: WJG
E Sun Paik, Yoo-Young Lee, Minhee Shim, Hyun Jin Choi, Tae-Joong Kim, Chel Hun Choi, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae
OBJECTIVE: The aim of this study was to analyse patterns and timing of recurrence and their association with clinical outcomes in recurrent epithelial ovarian cancer (EOC) patients with no gross residual disease after primary debulking surgery (PDS). METHODS: This study was conducted on 303 EOC patients with no residual disease after PDS who were treated at the Samsung Medical Center from 2002 to 2012. By reviewing electronic medical records, information on date of clinical/pathological recurrence and pattern of disease presentation for each relapse were retrieved...
September 9, 2016: Australian & New Zealand Journal of Obstetrics & Gynaecology
Michael J Overman, Harris S Soifer, Aaron Joel Schueneman, Joe Ensor, Volkan Adsay, Burcu Saka, Nastaran Neishaboori, Robert A Wolff, Huamin Wang, Catherine A Schnabel, Gauri Varadhachary
BACKGROUND: Ampullary adenocarcinoma is a rare gastrointestinal cancer associated with diverse outcomes due to clinical and pathological heterogeneity. Standardized methods to better prognosticate and inform therapeutic selection for ampullary adenocarcinoma are needed. This study explored the novel use and potential prognostic utility of a 92-gene cancer classifier in ampullary adenocarcinomas. METHODS: In this prospectively-defined, blinded study of ampullary adenocarcinoma [N =54; stage T3 or higher (57 %); Grade III (44 %); Node positive (55 %)], the performance of a 92-gene classifier was examined to predict the ampullary subtype that was derived from histomorphological examination of resected ampullary samples...
2016: BMC Cancer
Barbara C Worst, Cornelis M van Tilburg, Gnana Prakash Balasubramanian, Petra Fiesel, Ruth Witt, Angelika Freitag, Miream Boudalil, Christopher Previti, Stephan Wolf, Sabine Schmidt, Sasithorn Chotewutmontri, Melanie Bewerunge-Hudler, Matthias Schick, Matthias Schlesner, Barbara Hutter, Lenka Taylor, Tobias Borst, Christian Sutter, Claus R Bartram, Till Milde, Elke Pfaff, Andreas E Kulozik, Arend von Stackelberg, Roland Meisel, Arndt Borkhardt, Dirk Reinhardt, Jan-Henning Klusmann, Gudrun Fleischhack, Stephan Tippelt, Uta Dirksen, Heribert Jürgens, Christof M Kramm, Andre O von Bueren, Frank Westermann, Matthias Fischer, Birgit Burkhardt, Wilhelm Wößmann, Michaela Nathrath, Stefan S Bielack, Michael C Frühwald, Simone Fulda, Thomas Klingebiel, Ewa Koscielniak, Matthias Schwab, Roman Tremmel, Pablo Hernáiz Driever, Johannes H Schulte, Benedikt Brors, Andreas von Deimling, Peter Lichter, Angelika Eggert, David Capper, Stefan M Pfister, David T W Jones, Olaf Witt
The 'Individualized Therapy for Relapsed Malignancies in Childhood' (INFORM) precision medicine study is a nationwide German program for children with high-risk relapsed/refractory malignancies, which aims to identify therapeutic targets on an individualised basis. In a pilot phase, reported here, we developed the logistical and analytical pipelines necessary for rapid and comprehensive molecular profiling in a clinical setting. Fifty-seven patients from 20 centers were prospectively recruited. Malignancies investigated included sarcomas (n = 25), brain tumours (n = 23), and others (n = 9)...
September 2016: European Journal of Cancer
Lauren R Meltzer, Cathy D Meade, Diana B Diaz, Monica S Carrington, Thomas H Brandon, Paul B Jacobsen, Judith C McCaffrey, Eric B Haura, Vani N Simmons
We describe the series of iterative steps used to develop a smoking relapse-prevention intervention customized to the needs of cancer patients. Informed by relevant literature and a series of preliminary studies, an educational tool (DVD) was developed to target the unique smoking relapse risk factors among cancer patients. Learner verification interviews were conducted with 10 cancer patients who recently quit smoking to elicit feedback and inform the development of the DVD. The DVD was then refined using iterative processes and feedback from the learner verification interviews...
August 1, 2016: Journal of Cancer Education: the Official Journal of the American Association for Cancer Education
Jiaolin Zhou, Lianpeng Chang, Yanfang Guan, Ling Yang, Xuefeng Xia, Liqiang Cui, Xin Yi, Guole Lin
BACKGROUND: Liquid biopsy has been proposed to be a promising noninvasive tool to obtain information on tumor progression. Through a clinical observation of a case series of 6 consecutive patients, we aim to determine the value of circulating tumor DNA (ctDNA) for monitoring the tumor burden during the treatment of colorectal cancer (CRC). MATERIALS AND METHODS: We used capture sequencing of 545 genes to identify somatic alternations in primary tumor tissues of the six CRC patients who underwent radical surgery and in 23 plasma samples collected at serial time points...
2016: PloS One
Yoko Harima, Takayuki Ohguri, Hajime Imada, Hideyuki Sakurai, Tatsuya Ohno, Yoshiyuki Hiraki, Koh Tuji, Masahiro Tanaka, Hiromi Terashima
PURPOSE: To evaluate the effectiveness of whole-pelvic hyperthermia (HT) added to standard chemoradiotherapy (CRT) in locally advanced cervical cancer (CC), by investigating the clinical response and survival of patients treated with cisplatin-based CRT vs. CRT with HT (CRT + HT). MATERIALS AND METHODS: This study was conducted at five hospitals in Japan between September 2001 and March 2015 in patients with the International Federation of Gynecology and Obstetrics stage IB (bulky)-IVA CC undergoing definitive CRT...
November 2016: International Journal of Hyperthermia
Li Jalmsell, Malin Lövgren, Ulrika Kreicbergs, Jan-Inge Henter, Britt-Marie Frost
AIM: One in five children diagnosed with cancer will die from the disease. The aim of the study was to explore how children with cancer want to receive bad news about their disease, such as when no more treatment options are available. METHODS: We conducted individual interviews with ten children with cancer, aged seven to 17 years, at a single paediatric oncology unit in central Sweden. Interviews were audio-taped and analysed with systematic text condensation...
September 2016: Acta Paediatrica
Libni J Eapen, Edward Jones, Wassim Kassouf, Carole Lambert, Scott C Morgan, Madeleine Moussa, Robert Nam, Matthew Parliament, Laurie Russell, Fred Saad, D Robert Siemens, Luis Souhami, Ewa Szumacher, Scott Tyldesley, Yan Xu, Ingrid Zbieranowski, Rodney H Breau, Eric Belanger, Peter Black, Eric Estey, Julie Bowan, Bishwajit Bora, Michael Brundage, Peter Chung, Neil Fleshner, Andrew Evans, Glenn Bauman, Jonathan Izawa, Chris Davidson, Fadi Brimo
INTRODUCTION: We aimed to enumerate the rate of pelvic recurrence following radical cystectomy at university-affiliated hospitals in Canada. METHODS: Canadian, university-affiliated hospitals were invited to participate. They were asked to identify the first 10 consecutive patients undergoing radical cystectomy starting January 1, 2005, who had urothelial carcinoma stages pT3/T4 N0-2 M0. The first 10 consecutive cases starting January 1, 2005 who met these criteria were the patients submitted by that institution with information regarding tumour stage, age, number of nodes removed, and last known clinical status in regard to recurrence and patterns of failure...
March 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
Fo-Bao Lai, Wen-Ting Liu, Ying-Ying Jing, Guo-Feng Yu, Zhi-Peng Han, Xue Yang, Jian-Xing Zeng, Hang-Jie Zhang, Rong-Yu Shi, Xiao-Yong Li, Xiao-Rong Pan, Rong Li, Qiu-Dong Zhao, Meng-Chao Wu, Ping Zhang, Jing-Feng Liu, Li-Xin Wei
Due to the existence of cancer stem cells (CSCs), persistence and relapse of human hepatocellular carcinoma (HCC) are common after treatment with existing anti-cancer therapies. Emerging evidence indicates that lipopolysaccharide (LPS) plays a crucial role in aggravating HCC, but information about the effect of LPS on CSCs of HCC remains scant. Here, we report that the stemness of CD133(+) CSCs sorted from the human HCC cell line Huh7 was maintained well when cells were cultured with LPS. The reduction of CD133 expression was much lesser in cultured CSCs in the presence of LPS...
May 18, 2016: Cancer Letters
Lingjing Chen, Ingrid Glimelius, Martin Neovius, Sara Ekberg, Anna Martling, Sandra Eloranta, Karin E Smedby
BACKGROUND: The number of working-age rectal cancer survivors is increasing due to early detection and improved treatment. However, work loss duration and predictors among them have not been studied thoroughly. METHODS: We identified 3,438 patients with stage I-III rectal cancer, 18 to 61 years of age in the Swedish Colorectal Cancer Register 1996-2009. Information on work loss due to sick leave or disability pension was collected from 2 years before diagnosis to 5 years after (until December 31st, 2013)...
June 2016: Cancer Epidemiology, Biomarkers & Prevention
Woo Young Choi, Jun Ho Kim, Suk Jin Choi, Jisun Park, Young Hoon Park, Joo Han Lim, Moon Hee Lee, Chul Soo Kim, Hyeon Gyu Yi
Peritoneal lymphomatosis is a very rare disease of extranodal involvement of malignant lymphoma that is occasionally confounded with other peritoneal diseases. Herein, we reported the case of a 59-year-old woman who presented with massive ascites with prior history of stomach perforation during endoscopic procedure to treat early gastric cancer. Imaging studies showed massive ascites and tumor infiltration in the omentum and peritoneal wall. Initially, relapsed gastric cancer with peritoneal seeding was suspected based on the patient's history and imaging findings...
September 2016: Clinical Imaging
Kate Cahill, Nicola Lindson-Hawley, Kyla H Thomas, Thomas R Fanshawe, Tim Lancaster
BACKGROUND: Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). OBJECTIVES: To review the efficacy of nicotine receptor partial agonists, including varenicline and cytisine, for smoking cessation. SEARCH METHODS: We searched the Cochrane Tobacco Addiction Group's specialised register for trials, using the terms ('cytisine' or 'Tabex' or 'dianicline' or 'varenicline' or 'nicotine receptor partial agonist') in the title or abstract, or as keywords...
2016: Cochrane Database of Systematic Reviews
Lizhen Zhu, Caixia Dong, Ying Cao, Xuefeng Fang, Chenhan Zhong, Dan Li, Ying Yuan
BACKGROUND AND OBJECTIVE: Studies examining the prognostic value of the BRAF mutation on relapse-free survival (RFS), disease-free survival (DFS) and overall survival (OS) in stage II/III colorectal cancer (CRC) patients receiving curative resection and adjuvant chemotherapy so far showed discrepant results. Therefore, a meta-analysis of relevant studies was performed for clarification. METHODS: Randomized trials of stage II/III colorectal cancer treated with curative resection followed by adjuvant chemotherapy were selected to conduct a meta-analysis...
2016: PloS One
Justin A Nyborn, Maura Olcese, Taylor Nickerson, Jennifer W Mack
BACKGROUND: Physicians worry that disclosure of prognostic information can be distressing and deprive families of hope. Retrospective studies have shown that prognostic disclosure does not abrogate hope, but prospective data are lacking. OBJECTIVE: The study objective was to prospectively evaluate responses to prognosis communication among parents of children with advanced cancer. DESIGN: For this qualitative study we audiotaped conversations between clinicians and parents of children with newly relapsed or refractory cancer, and then interviewed parents about experiences with prognosis communication...
June 2016: Journal of Palliative Medicine
Christopher M Gallagher, Kenneth More, Tripthi Kamath, Anthony Masaquel, Annie Guerin, Raluca Ionescu-Ittu, Marjolaine Gauthier-Loiselle, Roy Nitulescu, Nicholas Sicignano, Elizabeth Butts, Eric Q Wu, Brian Barnett
Trastuzumab reduces the risk of relapse in women with HER2-positive non-metastatic breast cancer, but little information exists on the timing of trastuzumab initiation. The study investigated the impact of delaying the initiation of adjuvant trastuzumab therapy for >6 months after the breast cancer diagnosis on time to relapse, overall survival (OS), and relapse-free survival (RFS) among patients with non-metastatic breast cancer. Adult women with non-metastatic breast cancer who initiated trastuzumab adjuvant therapy without receiving any neoadjuvant therapy were selected from the US Department of Defense health claims database from 01/2003 to 12/2012...
May 2016: Breast Cancer Research and Treatment
Robert Chen, Suzanne Allibone, Nancy L Bartlett, Pauline Brice, Andy Chen, Katrina Pose, Lynn Rich, Vijay Bonthapally, Phillip M Garfin, Michelle Fanale
BACKGROUND: Patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two Phase II trials. With increased response rates and survival times, patient-reported outcomes (PROs) and health-related quality of life (HRQoL) are becoming increasingly important and can help inform treatment decisions to enhance care of cancer patients. OBJECTIVE: The objective was to qualitatively assess HRQoL in long-term survivors treated with BV...
2016: OncoTargets and Therapy
J C Teng, S M Lingaratnam, J A Trubiano, K A Thursky, M A Slavin, L J Worth
Pristinamycin has been used to treat a range of Gram-positive infections, but reported experience in patients with malignancy is limited. This study aimed to evaluate the use of pristinamycin in patients with cancer at an Australian centre. All patients commenced on oral pristinamycin therapy at the Peter MacCallum Cancer Centre between January 2005 and December 2014 were identified using the hospital pharmacy dispensing system. Information on demographics, co-morbidities, cancer diagnosis, infection characteristics, pristinamycin regimen, pristinamycin tolerability and outcomes was collected...
May 2016: International Journal of Antimicrobial Agents
Alexis Vrachimis, Lars Stegger, Christian Wenning, Benjamin Noto, Matthias Christian Burg, Julia Renate Konnert, Thomas Allkemper, Walter Heindel, Burkhard Riemann, Michael Schäfers, Matthias Weckesser
PURPOSE: The purpose of this study was to determine whether [(68)Ga]DOTATATE PET/MRI with diffusion-weighted imaging (DWI) can replace or complement [(18)F]FDG PET/CT in patients with radioactive-iodine (RAI)-refractory differentiated thyroid cancer (DTC). METHODS: The study population comprised 12 patients with elevated thyroglobulin and a negative RAI scan after thyroidectomy and RAI remnant ablation who underwent both [(18)F]FDG PET/CT and [(68)Ga]DOTATATE PET/MRI within 8 weeks of each other...
September 2016: European Journal of Nuclear Medicine and Molecular Imaging
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"